AKT1 and cancer: ( 27 , 28 ) Perifosine-only regimens failed to confirm the clinical response ( 29 ) but the blockage of AKT signaling seems to be effective in reprograming the molecular mechanisms of cancer cells and may act as an adjunct to therapy.